Delayed-onset hypothesis of antipsychotic action - A hypothesis tested and rejected

被引:334
作者
Agid, O
Kapur, S
Arenovich, T
Zipursky, RB
机构
[1] Univ Toronto, Ctr Addict & Mental Hlth, Schizophrenia Program, Toronto, ON M5T 1R8, Canada
[2] Univ Toronto, PET Ctr, Toronto, ON M5T 1R8, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada
[4] Univ Toronto, Dept Stat, Toronto, ON M5T 1R8, Canada
关键词
D O I
10.1001/archpsyc.60.12.1228
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Context: To understand the mechanism of action of antipsychotic drugs, it is critical to recognize the time course over which these medications take effect. Current models of antipsychotic action presume a "delayed onset" of action. Objective: To test the delayed-onset hypothesis of antipsychotic action via a meta-analytic study. Data Sources and Study Selection: Double-masked studies that reported results from active or placebo-controlled trials of antipsychotic response during the first 4 weeks of treatment were selected. These studies were identified by searching MEDLINE, 1996 to 2001; the Cumulative Index to Nursing and Allied Health, 1982 to 2001; EMBASE, 1980 to 2001; the ACP Journal Club; the Cochrane Database of Systematic Reviews; and the Database of Abstracts of Reviews of Effectiveness. Leads from these sources were followed up by manual searches. Data Synthesis: Forty-two published studies, including 7450 patients and 119 independent response vs time curves, were identified. Reductions in total scores on the Brief Psychiatric Rating Scale and the Positive and Negative Syndrome Scale were 13.8% during week 1,8.1% during week 2,4.2% during week 3, and 4.7% during week 4. This pattern of "early-onset" improvement was present even after the estimated effect of placebo treatment was removed and when results were restricted to the psychotic subscales of the scales. Conclusions: This analysis rejects the commonly held hypothesis that antipsychotic response is delayed. Rather, these findings suggest that the antipsychotic response starts in the first week of treatment and accumulates over time. Furthermore, greater improvement occurs in the first 2 treatment weeks than in the subsequent 2 treatment weeks. Proposed mechanisms of action of antipsychotic drugs need to account for this early-onset antipsychotic effect.
引用
收藏
页码:1228 / 1235
页数:8
相关论文
共 87 条
[1]   REMOXIPRIDE AND HALOPERIDOL IN SCHIZOPHRENIA - A DOUBLE-BLIND MULTICENTER STUDY [J].
AHLFORS, UG ;
RIMON, R ;
APPELBERG, B ;
HAGERT, U ;
HARMA, P ;
KATILA, H ;
MAHLANEN, A ;
MEHTONEN, OP ;
NAUKKARINEN, H ;
OUTAKOSKI, J ;
RANTANEN, H ;
SORRI, A ;
TAMMINEN, T ;
TOLVANEN, E ;
HOLM, AC .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 :99-103
[2]  
ANDERSEN J, 1990, J PSYCHIAT SCAND S, V358, P104
[3]  
ANDERSON WH, 1976, AM J PSYCHIAT, V133, P1076
[4]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[5]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137
[6]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[7]  
BECHELLI L P C, 1986, Encephale, V12, P121
[8]   Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients [J].
Blin, O ;
Azorin, JM ;
Bouhours, P .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (01) :38-44
[9]  
BORISON RL, 1992, PSYCHOPHARMACOL BULL, V28, P213
[10]  
BORISON RL, 1989, PSYCHOPHARMACOL BULL, V25, P190